| Market Cap | ₹50.53 CrMicro Cap |
|---|---|
| Annual Revenue | ₹50.66 Cr26.58% YoY Growth |
| PE Ratio | 6.98Sector PE: 41.56 |
| RSI | 45.55Neutral Zone |
Key highlights
- Product brand name officially registered as FOLIMAN Folic Acid Tablets
- Categorized as a Vitamin B-9 supplement under the healthcare and nutraceutical portfolio
- Initial launch focused on international markets with domestic rollout planned later
- Company reported annual revenue growth of 26.58% in the previous fiscal year
- Strategic move to strengthen market presence and enhance long-term business growth
The Product — What It Is
FOLIMAN is a Vitamin B-9 supplement designed as a Folic Acid Tablet, catering to the growing global demand for essential nutritional supplements. Folic acid is critical for DNA synthesis and repair, making it a staple in prenatal care and general health management. The product is categorized as a Healthcare, Nutraceutical, and Pharmaceutical offering, signifying its broad application across various health sectors.
By introducing this supplement, Shelter Pharma is addressing specific micronutrient deficiencies prevalent in global populations, positioning itself as a provider of foundational health solutions that meet rigorous international quality benchmarks for safety and efficacy.
Commercial Opportunity
The decision to launch FOLIMAN in international markets before the domestic Indian market indicates a strategy to capture higher-margin global demand. The global nutraceutical market is expanding rapidly, driven by increased health consciousness and a shift toward preventive healthcare. Shelter Pharma intends to leverage its existing manufacturing capabilities to provide quality-tested supplements that meet international standards.
Following the initial global rollout, the company plans a phased introduction into the Indian domestic market, allowing it to build brand equity abroad before competing in the local healthcare segment which is currently experiencing significant volume growth.
Strategic Fit
The launch of FOLIMAN aligns with the company's stated goal of continuous portfolio expansion within the healthcare and nutraceutical space. Shelter Pharma has traditionally focused on various pharmaceutical and herbal products; adding a vitamin supplement strengthens its presence in the preventive care category. This move is expected to enhance business growth opportunities and support long-term expansion strategies.
By diversifying its product range, the company aims to create sustainable value for its stakeholders while reducing reliance on any single therapy area, ensuring a more resilient revenue stream in the competitive pharmaceutical landscape.
Business Overview
Shelter Pharma, headquartered in Ahmedabad, operates in the Pharmaceuticals and Biotechnology sector with a focus on both human and animal healthcare products. The company has demonstrated consistent financial performance, reporting an annual revenue of 50.66 Cr and a healthy net profit of 7.24 Cr. With a return on equity (ROE) of 17.32% and a return on assets (ROA) of 14.97%, the firm maintains efficient operational margins compared to its peers.
The current promoter holding stands at 44.99%, reflecting stable management control as the company enters new international territories and expands its nutraceutical footprint.
| Share price | ₹30.01 |
|---|---|
| Market capitalisation | ₹50.53 Cr |
| Revenue (annual) | ₹50.66 Cr |
| Net profit (annual) | ₹7.24 Cr |
| P/E (TTM) | 6.98×Sector 41.56× |
| Promoter holding | 44.99% |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Shelter Pharma Ltd announcing the launch of FOLIMAN Folic Acid Tablets in the international market. Market figures from a third-party data provider.
